Thursday, August 27, 2015

Granting of patent for an advanced cardiac biomarker is expected to transform the cardiac biomarker industry

The area of diagnosing and treatment
of various cardiovascular diseases have undergone a paradigm change with the
introduction of cardiac biomarker. By monitoring the various heart conditions biomarkers can
potentially be used to detect and monitor a wide range of cardiac conditions in
the critical care setting.

Singulex, Inc., recently announced
that the Japanese Patent Office has granted a crucial patent which covers methods
for detecting or monitoring cardiovascular conditions by the use of biomarkers Interleukin
17-A (IL-17A)and cardiac Troponin-I
(cTnI) in assays which have high sensitivity.

Japanese Patent No. 5678045,
entitled “Highly Sensitive Biomarker Panels”’ provides patent protection in
Japan and it expires by June 2029. The patent is an important development in
the industrial landscape of cardiac biomarker recent market dynamics as it
impacts the Company's portfolio of 22 issued patents which are connected to its
core SMCTM technology and biomarker assays. The company was previously granted
United States Patent 8,450,069 covering methods for assessing cardiovascular
health and damage by the use of biomarkers cTnI, IL-6, and IL-17A, along with
one or more of BNP & TNF-a, in
platform-independent highly sensitive assays. This patent provides the company
exclusive commercial rights in US to conduct these these assays through June
2030.

Moreover, as claimed by Japanese
patent, one or more of Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha
(TNF-a), along with different forms of B-type natriuretic peptides are used in
combination with cTnI and IL-17A as an effective biomarker.

Guido Baechler, President and
Chief Executive Officer of Singulex., “We are committed to advancing the
clinical understanding and use of high sensitivity biomarkers for the
management of chronic diseases, and I am pleased with the continued progress of
our clinical programs that support our CLIA-licensed laboratory business as
well as our emerging in vitro Diagnostics business, all based upon our Single
Molecule Counting technology,"

There are many prominent
diagnostic companies which have recently introduced immunoassays for cardiac
biomarker testing on an integrated platform, and the leading vendors are
pro-active in increasing the efficacy of the systems so that the results are
accurate and fast. Prominent market players include Abbott Laboratories, Roche
Diagnostics, Alere Inc, Siemens Healthcare, Dickinson and Company and Becton,
Bio-Rad Laboratories, and BioMerieux, Randox laboratories.

Recently, Big
Market Research has added a report titled “World Cardiac Biomarkers - Market
Opportunities and Forecasts, 2014 -2020”. The report offers a comprehensive
insights into the current and future market trends, market profile of leading
market players along with detailed segmentation and forecast.